Buisman Florian E, van Gelder Linda, Menke-Pluijmers Marian B E, Bisschops Bob H C, Plaisier Peter W, Westenend Pieter J
Department of Surgery, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Department of Surgery, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
World J Surg Oncol. 2016 Jun 23;14(1):166. doi: 10.1186/s12957-016-0915-4.
Breast cancer is a common malignancy, but metastases to the breast of extramammary malignancies are very rare. Treatment and prognosis are different. The aim of the study is to report the incidence of lymphomas and metastases to the breast of extramammary malignancies in our 30-year archive.
The pathology database of a single institute was reviewed for all breast neoplasms which were coded in our system as a metastasis in the period 1985-2014. Metastatic tumors from primary breast carcinoma were excluded.
A total of 47 patients were included (7 men/40 women, mean age 63 years). The majority originated from lymphoma (n = 18) and primary melanoma (n = 11). Other primary tumor sites included the ovary (n = 6), lung (n = 6), colon (n = 3), kidney (n = 1), stomach (n = 1), and chorion (n = 1). In 24/47 patients (51 %), metastasis was the first sign of the specific malignant disease. In seven patients (15 %) surgery was performed, the diagnosis of metastatic disease was adjusted in four patients (9 %) postoperatively.
It is important to distinguish lymphomas and metastases to the breast from common primary breast carcinoma for proper treatment and prognosis. Therefore, we emphasize the need for a histological or cytopathological diagnosis before any treatment is commenced. The pathologist plays a key role in considering the diagnosis of metastasis if the histological features are unusual for a primary breast carcinoma. The pathologist should therefore be properly informed by the clinical physician although lymphomas and metastases to the breast are the first presentation of malignant disease in half the cases.
乳腺癌是一种常见的恶性肿瘤,但乳腺外恶性肿瘤转移至乳腺的情况非常罕见。治疗方法和预后有所不同。本研究的目的是报告我们30年存档中淋巴瘤及乳腺外恶性肿瘤转移至乳腺的发生率。
回顾了一家机构的病理数据库,纳入1985年至2014年期间在我们系统中编码为转移瘤的所有乳腺肿瘤。排除原发性乳腺癌转移瘤。
共纳入47例患者(7例男性/40例女性,平均年龄63岁)。大多数起源于淋巴瘤(n = 18)和原发性黑色素瘤(n = 11)。其他原发肿瘤部位包括卵巢(n = 6)、肺(n = 6)、结肠(n = 3)、肾(n = 1)、胃(n = 1)和绒毛膜(n = 1)。在24/47例患者(51%)中,转移是特定恶性疾病的首发症状。7例患者(15%)接受了手术,4例患者(9%)术后调整了转移性疾病的诊断。
为了进行恰当的治疗和判断预后,区分淋巴瘤及乳腺外恶性肿瘤转移至乳腺与常见的原发性乳腺癌很重要。因此,我们强调在开始任何治疗之前需要进行组织学或细胞病理学诊断。如果原发性乳腺癌的组织学特征不寻常,病理学家在考虑转移瘤的诊断中起着关键作用。因此,尽管在一半的病例中淋巴瘤及乳腺外恶性肿瘤转移至乳腺是恶性疾病的首发表现,但临床医生仍应及时向病理学家提供充分信息。